RU2013118544A - METHOD FOR DIAGNOSTIC OF METABOLIC DISORDERS IN PATIENTS WITH Urolithiasis CAUSED BY PURIN METABOLIC DISORDERS - Google Patents

METHOD FOR DIAGNOSTIC OF METABOLIC DISORDERS IN PATIENTS WITH Urolithiasis CAUSED BY PURIN METABOLIC DISORDERS Download PDF

Info

Publication number
RU2013118544A
RU2013118544A RU2013118544/15A RU2013118544A RU2013118544A RU 2013118544 A RU2013118544 A RU 2013118544A RU 2013118544/15 A RU2013118544/15 A RU 2013118544/15A RU 2013118544 A RU2013118544 A RU 2013118544A RU 2013118544 A RU2013118544 A RU 2013118544A
Authority
RU
Russia
Prior art keywords
metabolic disorders
urolithiasis
patients
caused
purin
Prior art date
Application number
RU2013118544/15A
Other languages
Russian (ru)
Inventor
Александр Игоревич Стрельников
Андрей Владимирович Кустов
Вячеслав Николаевич Тростин
Борис Григорьевич Сафронов
Original Assignee
Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации filed Critical Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации
Priority to RU2013118544/15A priority Critical patent/RU2013118544A/en
Publication of RU2013118544A publication Critical patent/RU2013118544A/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Способ диагностики метаболических нарушений у пациентов с мочекаменной болезнью, вызванной нарушениями пуринового обмена путем анализа состава мочевых конкрементов методом порошковой дифрактометрии, отличающийся тем, что идентифицируют и количественно определяют состав всех минералогических фаз исследуемых образцов, на основе чего относят пациента к одной из восьми групп и выбирают соответствующий алгоритм диагностики.A method for diagnosing metabolic disorders in patients with urolithiasis caused by impaired purine metabolism by analyzing the composition of urinary calculi by powder diffractometry, characterized in that the composition of all mineralogical phases of the samples is identified and quantified, based on which the patient is assigned to one of eight groups and selected appropriate diagnostic algorithm.

Claims (1)

Способ диагностики метаболических нарушений у пациентов с мочекаменной болезнью, вызванной нарушениями пуринового обмена путем анализа состава мочевых конкрементов методом порошковой дифрактометрии, отличающийся тем, что идентифицируют и количественно определяют состав всех минералогических фаз исследуемых образцов, на основе чего относят пациента к одной из восьми групп и выбирают соответствующий алгоритм диагностики. A method for diagnosing metabolic disorders in patients with urolithiasis caused by impaired purine metabolism by analyzing the composition of urinary calculi by powder diffractometry, characterized in that the composition of all mineralogical phases of the samples is identified and quantified, based on which the patient is assigned to one of eight groups and selected appropriate diagnostic algorithm.
RU2013118544/15A 2013-04-22 2013-04-22 METHOD FOR DIAGNOSTIC OF METABOLIC DISORDERS IN PATIENTS WITH Urolithiasis CAUSED BY PURIN METABOLIC DISORDERS RU2013118544A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2013118544/15A RU2013118544A (en) 2013-04-22 2013-04-22 METHOD FOR DIAGNOSTIC OF METABOLIC DISORDERS IN PATIENTS WITH Urolithiasis CAUSED BY PURIN METABOLIC DISORDERS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013118544/15A RU2013118544A (en) 2013-04-22 2013-04-22 METHOD FOR DIAGNOSTIC OF METABOLIC DISORDERS IN PATIENTS WITH Urolithiasis CAUSED BY PURIN METABOLIC DISORDERS

Publications (1)

Publication Number Publication Date
RU2013118544A true RU2013118544A (en) 2014-10-27

Family

ID=53380541

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013118544/15A RU2013118544A (en) 2013-04-22 2013-04-22 METHOD FOR DIAGNOSTIC OF METABOLIC DISORDERS IN PATIENTS WITH Urolithiasis CAUSED BY PURIN METABOLIC DISORDERS

Country Status (1)

Country Link
RU (1) RU2013118544A (en)

Similar Documents

Publication Publication Date Title
CY1121203T1 (en) THERAPEUTIC USES OF EMPAGLIFLOSINE
MX2021006897A (en) Cell-free nucleic acids for the analysis of the human microbiome and components thereof.
CL2013002573A1 (en) Composition comprising an extract or preparation of human feces; method to replace or complement or modify the microbiota of a subject's colon; use of said composition to treat disease or pathological or iatrogenic condition of the colon.
IL282923A (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
AR092818A1 (en) HUMANIZED TAU ANTIBODY
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
CL2015002724A1 (en) Methods to treat crohn's disease using an anti-il23 antibody
BR112014026661A2 (en) in vitro method for cancer diagnosis and surveillance
BR112017025995A2 (en) igfbp3 inhibitor, pharmaceutical composition for use in the treatment and / or prevention of an intestinal disorder, method for the diagnosis of an intestinal disorder in an individual and kit for the diagnosis of an intestinal disorder
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
BR102012002812A8 (en) method to determine the influence of a variable on a phenomenon
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
IN2015DN00515A (en)
MX2015016120A (en) Binding molecules that bind human complement factor c2 and uses thereof.
BR112015027249A2 (en) cancer diagnosis method
IL245163A0 (en) Kit and method for collecting body fluid for medical diagnosis
BR112015020061A2 (en) caix stratification-based cancer treatment
MX2021007569A (en) Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof.
BR112015017432A2 (en) methods for treating cardiovascular indications
WO2014169011A3 (en) Methods for treating immune diseases
MX2015009726A (en) Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment.
RU2013118544A (en) METHOD FOR DIAGNOSTIC OF METABOLIC DISORDERS IN PATIENTS WITH Urolithiasis CAUSED BY PURIN METABOLIC DISORDERS
BR112017027304A2 (en) method for the diagnosis of farber's disease
WO2015092444A3 (en) Biomarkers